EUVIMEDEUVIMED entdecken
Crossref

Investigation of Methylsulfonamide’s Capability to Prevent Zn 2+ -Induced Aβ Peptide Aggregation Based on Zn 2+ Coordination within the Zinc Binding Region of Aβ for Treatment of Alzheimer’s Disease (AD)

Demet Ataman Sadık iD, Cemre Sare Cansız, Merve Turğut, Çağdaş Dağ iD, Memed Duman

ACS Chemical Neuroscience · 2025

DOI: 10.1021/acschemneuro.5c00238 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Chemical Neuroscience, 2025. Verfasst von Demet Ataman Sadık und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Natural and Applied Sciences, Division of Nanotechnology and Nanomedicine, Hacettepe University, 06800 Ankara, Turkey. Hauptthemen laut MEDLINE: Amyloid beta-Peptides, Zinc, Alzheimer Disease, Sulfonamides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: T?rkiye Bilimsel ve Teknolojik Arastirma Kurumu.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There is no cure for Alzheimer's disease (AD) with the currently suggested therapies. Thus, designing and synthesis of new drugs for the treatment of Alzheimer's disease for safe and effective therapy have become an important task. Metal ions such as Zn2+, Cu2+, and Fe3+ are known to increase the rate of Aβ aggregation and exist in amyloid plaques at high concentrations. Aβ oligomers, whether formed on the way to amyloid fibril formation or formed off-pathway due to the interaction of Aβ monomers with Zn2+, are considered to be the most neurotoxic aggregates. Using NMR and SPR, this study reports the methylsulfonamide inhibition of Zn2+-induced Aβ1-16 dimer formation via methylsulfonamide coordination of Zn2+ within the Zn2+ binding region of Aβ, (11EVHH14) and inhibit the H14-Zn2+ coordination between the 11EVHH14 regions of two Aβ peptides, preventing their interactions and hence the Aβ dimer formation. According to the results of this study, methylsulfonamide has the potential to be used as a drug in Alzheimer's disease for the prevention of the formation of the Zn2+-induced toxic Aβ oligomers formed during Aβ aggregation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid beta-PeptidesZincAlzheimer DiseaseSulfonamidesPeptide FragmentsHumansProtein AggregatesProtein Aggregation, Pathological

Stichwörter der Autor:innen

Alzheimer’s diseaseNMRSPRZn2+ coordinationZn2+-induced Aβ1−16 dimer formationmethylsulfonamide inhibition

Substanzen

Amyloid beta-PeptidesZincSulfonamidesPeptide FragmentsProtein Aggregatesamyloid beta-protein (1-16)

Autor:innen und Institutionen

  • Institute of Natural and Applied Sciences, Division of Nanotechnology and Nanomedicine, Hacettepe University, 06800 Ankara, Turkey.
  • Nanofabrication and Nanocharacterization Center for Scientific and Technological Advanced Research (n2STAR), Koç University, 34450 Istanbul, Turkey.
  • Koç University Işbank Center for Infectious Diseases (KUISCID), Koç University, 34450 Istanbul, Türkiye.

ORCID-Profile: Demet Ataman Sadık, Çağdaş Dağ

Förderung

  • T?rkiye Bilimsel ve Teknolojik Arastirma Kurumu

Zitieren

APA

Ataman Sadık, D., Cansız, C. S., Turğut, M., Dağ, Ç., & Duman, M. (2025). Investigation of Methylsulfonamide’s Capability to Prevent Zn 2+ -Induced Aβ Peptide Aggregation Based on Zn 2+ Coordination within the Zinc Binding Region of Aβ for Treatment of Alzheimer’s Disease (AD). ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.5c00238

Vancouver

Ataman Sadık D, Cansız CS, Turğut M, Dağ Ç, Duman M. Investigation of Methylsulfonamide’s Capability to Prevent Zn 2+ -Induced Aβ Peptide Aggregation Based on Zn 2+ Coordination within the Zinc Binding Region of Aβ for Treatment of Alzheimer’s Disease (AD). ACS Chemical Neuroscience. 2025. doi:10.1021/acschemneuro.5c00238

BibTeX
@article{AtamanSadk2025,
  author = {Ataman Sadık, Demet and Cansız, Cemre Sare and Turğut, Merve and Dağ, Çağdaş and Duman, Memed},
  title = {Investigation of Methylsulfonamide’s Capability to Prevent Zn 2+ -Induced Aβ Peptide Aggregation Based on Zn 2+ Coordination within the Zinc Binding Region of Aβ for Treatment of Alzheimer’s Disease (AD)},
  journal = {ACS Chemical Neuroscience},
  year = {2025},
  doi = {10.1021/acschemneuro.5c00238}
}
Kostenlos starten →